56.70
+7.18%
Close of 9 Nov 2026, in TWD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About U-Neuron Biomedical
Its shares trade on Taipei Exchange under the ticker 6973.TWO. It has been listed since 20 July 2023. In the fiscal year to 31 December 2024, it reported revenue of TWD 46.2m and a net loss of TWD 60.0m. At that date it held total assets of TWD 846.7m and shareholders' equity of TWD 811.4m.
U-Neuron Biomedical Inc is a TW-based company operating in Biotechnology industry. The company is headquartered in Taipei, New Taipei. The company went IPO on 2023-07-20. U-Neuron Biomedical Inc is a Taiwan-based company mainly engaged in the development of cosmetics, health care consumer products and new drugs. In the part of new drug development, allogeneic amniotic fluid stem cells and their derivatives are used as the main body, and the excellent regeneration ability of amniotic fluid stem cells is used to develop a variety of suitable applications. In the part of cosmetics and health care consumer products, a series of medical beauty and health care products have been developed with deer amniotic fluid stem cell derivatives as the main axis. The new drug development products include UA002 for the treatment of erectile dysfunction and UB003 for the treatment of dry eye. The cosmetics and health care consumer products include masks, essences, and creams for anti-aging, repairing and moisturizing, moisturizing and translucent. The products are mainly sold domestically.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 20 Jul 2023
- Website
- u-neuron.com ↗
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Taiwan-based U-Neuron Biomedical Inc develops innovative stem cell therapies in Health Care sector.
- U-Neuron Biomedical Inc focuses on allogeneic amniotic fluid stem cells for new drug development.
- Taiwan market offers strong domestic demand for U-Neuron Biomedical Inc's cosmetic and health care products.
Weaknesses
- U-Neuron Biomedical Inc's new drug development products like UA002 and UB003 are still in early stages.
- Taiwan-based U-Neuron Biomedical Inc has limited international market presence.
- U-Neuron Biomedical Inc's product range is concentrated in cosmetics and health care consumer products.
Opportunities
- Taiwan's Health Care sector growth supports U-Neuron Biomedical Inc's expansion.
- U-Neuron Biomedical Inc can leverage allogeneic amniotic fluid stem cells for new applications.
- Taiwan's cosmetic market offers opportunities for U-Neuron Biomedical Inc's anti-aging products.
Threats
- U-Neuron Biomedical Inc faces competition from established Health Care companies in Taiwan.
- Taiwan's regulatory environment may impact U-Neuron Biomedical Inc's new drug approvals.
- U-Neuron Biomedical Inc's reliance on domestic sales exposes it to local market risks.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.